As Puma Biotechnology (PBYI) struggles to meet sales goals and expand usage for its all-important Nerlynx breast cancer treatment, the company has resorted to a tried-and-true tactic for boosting sales — raising prices. But Puma has taken a step most other drug makers have avoided recently: The wholesale price for Nerlynx not only jumped twice this year, but by 9.9% each time.
In other words, Puma has now increased the price by 20% in just nine months.
About the Author Reprints
